Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967381 · ClinicalTrials.gov registry record · Early Phase 1
Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse
A Early Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse, sponsored by University of Kentucky.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT01967381 is a Early Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse that has completed, run by University of Kentucky. The registered enrollment target is 24 participants, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01967381, a Early Phase 1 study of Methamphetamine-dependence and Methamphetamine Abuse, has completed, sponsored by University of Kentucky.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human laboratory study will be conducted. The proposed study is innovative and important because it will provide the impetus for the conduct of double blind, placebo-controlled trials to further demonstrate the efficacy of combined oxazepam and naltrexone for managing methamphetamine dependence.
Conditions Studied
Interventions
- DRUG Methamphetamine (Desoxyn®)
Study Locations (1)
Kentucky
- University of Kentucky Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01967381
The ClinicalTrials.gov registry entry for NCT01967381 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 105-participant average among 18 other Methamphetamine-dependence trials with a reported enrollment target (77% lower). The listed sponsor is University of Kentucky, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Methamphetamine-dependence appearing as the primary indexed condition, and to 1 intervention - of which Methamphetamine (Desoxyn®) is the first listed.
NCT01967381 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT01967381 about?
NCT01967381 is a clinical study titled "Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse". The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human laboratory study will be conducte...
What is the current status of trial NCT01967381?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2013-10. Estimated completion is 2018-09.
What conditions does trial NCT01967381 study?
This clinical trial studies the following conditions: Methamphetamine-dependence, Methamphetamine Abuse.
What interventions are being tested in trial NCT01967381?
The interventions under investigation include: Methamphetamine (Desoxyn®) (DRUG).
Who is sponsoring clinical trial NCT01967381?
This trial is sponsored by University of Kentucky, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01967381 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methamphetamine-dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRevention Of Methamphetamine Use Among Postpartum Women Trial (PROMPT)
RECRUITING · Early Phase 1
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
RECRUITING · Phase 3
-
Encouraging Abstinence Behavior in a Drug Epidemic: Optimizing Dynamic Incentives
RECRUITING · NA
-
rTMS for Craving in Methamphetamine Use Disorder
RECRUITING · NA
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.